BioSpace News Archive

Intergalactic Therapeutics, a company focused on transforming medicine through non-viral gene therapy, announced today positive preclinical results from its lead program IG-002 addressing all forms of ABCA4-related retinopathies.

Stoke Therapeutics, Inc. today announced that the FDA will allow the administration of a higher single dose of STK-001 (70mg) in its ongoing Phase 1/2a MONARCH study of children and adolescents with Dravet syndrome.

Exscientia plc (Nasdaq: EXAI) today announced that four abstracts have been accepted for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, being held April 14-19, 2023.

Silence Therapeutics plc today reported its financial results for the fourth quarter and full year ended December 31, 2022 and reviewed recent business highlights.

LumiThera Inc. today announced the 24-month data from its LIGHTSITE III, multi-center clinical trial which demonstrated sustained vision improvement in dry Age-Related Macular Degeneration (AMD) subjects treated with the Valeda ® Light Delivery System.

NEXGEL, Inc. today announced it will report its financial results for the fourth quarter and full year periods ended December 31, 2022, after the market closes on March 27, 2023.

Werewolf Therapeutics, Inc. today announced the publication of an abstract summarizing an upcoming poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023.

Internationally acclaimed clinical geneticist Reed Pyeritz, MD, PhD, FACMG, is the recipient of the 2023 ACMG Foundation for Genetic and Genomic Medicine’s David L. Rimoin Lifetime Achievement Award in Medical Genetics.

Compugen Ltd. today announced that it will present new research enabling accurate detection and study of the functional relevance of the novel target PVRIG following correction of the GENCODE gene model, at the American Association for Cancer Research (AACR) annual meeting on April 14-19, 2023, in Orlando, Florida.

Clario today announced Rod MacKenzie CMG, PhD. as their new Chairman of the Board of Directors.